Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Retinal Detachment | 10 | 2024 | 429 | 2.660 |
Why?
|
Diabetic Retinopathy | 19 | 2024 | 1299 | 2.450 |
Why?
|
Visual Acuity | 30 | 2024 | 2714 | 2.420 |
Why?
|
Fluorescein Angiography | 25 | 2024 | 1086 | 2.330 |
Why?
|
Core Binding Factor Alpha 2 Subunit | 6 | 2024 | 357 | 2.310 |
Why?
|
Tomography, Optical Coherence | 35 | 2024 | 2958 | 1.950 |
Why?
|
Vitreoretinopathy, Proliferative | 4 | 2024 | 76 | 1.800 |
Why?
|
Retinal Vessels | 16 | 2024 | 864 | 1.540 |
Why?
|
Vitrectomy | 13 | 2024 | 392 | 1.510 |
Why?
|
Retinal Diseases | 4 | 2023 | 711 | 1.390 |
Why?
|
Epiretinal Membrane | 5 | 2023 | 73 | 1.240 |
Why?
|
Intravitreal Injections | 7 | 2024 | 401 | 1.200 |
Why?
|
Contrast Sensitivity | 10 | 2024 | 253 | 1.160 |
Why?
|
Choroidal Neovascularization | 2 | 2020 | 364 | 1.120 |
Why?
|
Retinal Pigment Epithelium | 6 | 2024 | 309 | 1.110 |
Why?
|
Macular Edema | 5 | 2024 | 387 | 1.070 |
Why?
|
Retina | 13 | 2022 | 2663 | 1.050 |
Why?
|
Academies and Institutes | 3 | 2024 | 326 | 1.000 |
Why?
|
Angiogenesis Inhibitors | 7 | 2024 | 2062 | 0.950 |
Why?
|
Receptors, Fibroblast Growth Factor | 2 | 2023 | 196 | 0.880 |
Why?
|
Retinal Neovascularization | 5 | 2024 | 288 | 0.790 |
Why?
|
Fundus Oculi | 11 | 2024 | 560 | 0.790 |
Why?
|
Helminths | 1 | 2022 | 39 | 0.780 |
Why?
|
Ophthalmology | 3 | 2024 | 560 | 0.750 |
Why?
|
Furin | 1 | 2021 | 46 | 0.740 |
Why?
|
Retinal Vein Occlusion | 4 | 2024 | 149 | 0.730 |
Why?
|
Retinal Perforations | 6 | 2024 | 138 | 0.720 |
Why?
|
Macular Degeneration | 5 | 2024 | 1016 | 0.710 |
Why?
|
Uveal Neoplasms | 1 | 2023 | 344 | 0.710 |
Why?
|
Uveitis | 1 | 2024 | 398 | 0.700 |
Why?
|
Endophthalmitis | 1 | 2023 | 262 | 0.690 |
Why?
|
Glucocorticoids | 3 | 2024 | 2170 | 0.630 |
Why?
|
Craniocerebral Trauma | 1 | 2023 | 496 | 0.630 |
Why?
|
Macula Lutea | 4 | 2024 | 180 | 0.620 |
Why?
|
Quinoxalines | 1 | 2020 | 297 | 0.620 |
Why?
|
Vascular Endothelial Growth Factor A | 10 | 2024 | 3520 | 0.620 |
Why?
|
Wet Macular Degeneration | 1 | 2020 | 165 | 0.610 |
Why?
|
SEER Program | 1 | 2023 | 1476 | 0.610 |
Why?
|
Graves Ophthalmopathy | 2 | 2020 | 135 | 0.600 |
Why?
|
Accidents, Traffic | 1 | 2023 | 821 | 0.590 |
Why?
|
Cataract Extraction | 1 | 2022 | 465 | 0.580 |
Why?
|
Corneal Diseases | 1 | 2023 | 539 | 0.560 |
Why?
|
Pulmonary Fibrosis | 1 | 2021 | 507 | 0.560 |
Why?
|
Retinal Vasculitis | 1 | 2016 | 46 | 0.530 |
Why?
|
Cataract | 1 | 2022 | 837 | 0.510 |
Why?
|
Retinopathy of Prematurity | 1 | 2020 | 449 | 0.500 |
Why?
|
Neovascularization, Pathologic | 4 | 2023 | 2643 | 0.500 |
Why?
|
Blood Vessels | 1 | 2021 | 1112 | 0.500 |
Why?
|
Small Molecule Libraries | 1 | 2020 | 746 | 0.490 |
Why?
|
Lymphangiogenesis | 1 | 2016 | 172 | 0.480 |
Why?
|
Potassium Channels, Voltage-Gated | 3 | 2004 | 142 | 0.480 |
Why?
|
Blood-Brain Barrier | 1 | 2021 | 1034 | 0.470 |
Why?
|
Recombinant Fusion Proteins | 3 | 2022 | 3735 | 0.450 |
Why?
|
MAP Kinase Signaling System | 1 | 2020 | 1489 | 0.440 |
Why?
|
Central Serous Chorioretinopathy | 2 | 2024 | 32 | 0.420 |
Why?
|
Sequence Analysis, RNA | 1 | 2021 | 2038 | 0.420 |
Why?
|
Potassium Channels | 3 | 2004 | 538 | 0.410 |
Why?
|
Scleral Buckling | 4 | 2024 | 95 | 0.410 |
Why?
|
Giant Cell Arteritis | 1 | 2016 | 307 | 0.400 |
Why?
|
Tissue Plasminogen Activator | 1 | 2018 | 1166 | 0.390 |
Why?
|
Endotamponade | 2 | 2024 | 37 | 0.390 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2020 | 4362 | 0.390 |
Why?
|
Presenilin-1 | 3 | 2021 | 669 | 0.370 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 5 | 2024 | 665 | 0.370 |
Why?
|
Vitreous Body | 3 | 2024 | 400 | 0.360 |
Why?
|
Photography | 4 | 2024 | 537 | 0.360 |
Why?
|
Methotrexate | 1 | 2017 | 1722 | 0.360 |
Why?
|
Nervous System Diseases | 1 | 2021 | 1668 | 0.360 |
Why?
|
Endothelial Cells | 2 | 2020 | 3586 | 0.350 |
Why?
|
Medicaid | 1 | 2023 | 2843 | 0.340 |
Why?
|
Pyrazoles | 1 | 2020 | 2024 | 0.340 |
Why?
|
Tamoxifen | 1 | 2014 | 968 | 0.330 |
Why?
|
Single-Cell Analysis | 1 | 2021 | 2531 | 0.330 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2016 | 1660 | 0.320 |
Why?
|
Calcium-Binding Proteins | 2 | 2004 | 1085 | 0.320 |
Why?
|
Eye | 1 | 2012 | 715 | 0.300 |
Why?
|
Brachytherapy | 2 | 2013 | 1227 | 0.300 |
Why?
|
Uveomeningoencephalitic Syndrome | 1 | 2008 | 22 | 0.300 |
Why?
|
Humans | 87 | 2024 | 768369 | 0.290 |
Why?
|
Immunosuppressive Agents | 2 | 2017 | 4213 | 0.260 |
Why?
|
Disease Models, Animal | 10 | 2024 | 18390 | 0.260 |
Why?
|
Melanins | 1 | 2008 | 290 | 0.250 |
Why?
|
Respiration | 1 | 2012 | 1667 | 0.250 |
Why?
|
Syphilis | 1 | 2008 | 242 | 0.240 |
Why?
|
Microvessels | 4 | 2024 | 586 | 0.240 |
Why?
|
Movement | 1 | 2012 | 1489 | 0.240 |
Why?
|
Melanoma | 1 | 2023 | 5740 | 0.240 |
Why?
|
Eye Infections, Bacterial | 1 | 2008 | 241 | 0.240 |
Why?
|
Silicone Oils | 1 | 2024 | 22 | 0.240 |
Why?
|
Fluocinolone Acetonide | 1 | 2024 | 38 | 0.230 |
Why?
|
Radiation Dosage | 1 | 2013 | 1974 | 0.230 |
Why?
|
Receptor, TIE-2 | 1 | 2024 | 182 | 0.220 |
Why?
|
Glaucoma, Neovascular | 1 | 2023 | 37 | 0.220 |
Why?
|
Choroid | 2 | 2024 | 363 | 0.220 |
Why?
|
Male | 46 | 2024 | 364761 | 0.220 |
Why?
|
Drug Implants | 1 | 2024 | 231 | 0.220 |
Why?
|
Vitreous Detachment | 1 | 2023 | 23 | 0.220 |
Why?
|
Apolipoprotein E3 | 2 | 2023 | 107 | 0.220 |
Why?
|
Triamcinolone Acetonide | 1 | 2024 | 105 | 0.220 |
Why?
|
Motorcycles | 1 | 2023 | 42 | 0.210 |
Why?
|
Protective Devices | 1 | 2023 | 72 | 0.210 |
Why?
|
Cells, Cultured | 5 | 2021 | 19035 | 0.210 |
Why?
|
Ions | 1 | 2003 | 257 | 0.210 |
Why?
|
Alzheimer Disease | 5 | 2023 | 8723 | 0.210 |
Why?
|
Lung | 1 | 2021 | 10090 | 0.200 |
Why?
|
Head Protective Devices | 1 | 2023 | 118 | 0.200 |
Why?
|
Female | 44 | 2024 | 396926 | 0.190 |
Why?
|
Middle Aged | 33 | 2024 | 223406 | 0.190 |
Why?
|
Retrospective Studies | 20 | 2024 | 81835 | 0.180 |
Why?
|
Retinal Vein | 1 | 2021 | 47 | 0.180 |
Why?
|
Vitreous Hemorrhage | 1 | 2021 | 47 | 0.180 |
Why?
|
Oxazolone | 1 | 2020 | 61 | 0.180 |
Why?
|
Cell Separation | 2 | 2017 | 1725 | 0.180 |
Why?
|
Diagnostic Techniques, Ophthalmological | 2 | 2024 | 252 | 0.180 |
Why?
|
Aged | 27 | 2024 | 171514 | 0.170 |
Why?
|
Retinal Artery | 1 | 2021 | 109 | 0.170 |
Why?
|
Bleomycin | 1 | 2021 | 495 | 0.170 |
Why?
|
Fovea Centralis | 1 | 2020 | 126 | 0.170 |
Why?
|
Diabetes Mellitus | 3 | 2023 | 5887 | 0.170 |
Why?
|
Adult | 28 | 2024 | 223528 | 0.170 |
Why?
|
Contrast Media | 1 | 2013 | 5337 | 0.160 |
Why?
|
Eye Diseases, Hereditary | 1 | 2020 | 122 | 0.160 |
Why?
|
Follow-Up Studies | 13 | 2024 | 39429 | 0.160 |
Why?
|
Coloring Agents | 2 | 2020 | 564 | 0.160 |
Why?
|
Dexamethasone | 2 | 2024 | 1965 | 0.160 |
Why?
|
Apolipoprotein E4 | 1 | 2023 | 712 | 0.160 |
Why?
|
Indicators and Reagents | 1 | 2020 | 455 | 0.160 |
Why?
|
Animals | 21 | 2024 | 169424 | 0.160 |
Why?
|
Myopia | 1 | 2021 | 252 | 0.160 |
Why?
|
Glycolysis | 1 | 2023 | 838 | 0.160 |
Why?
|
Laser Coagulation | 1 | 2020 | 333 | 0.150 |
Why?
|
Choroiditis | 1 | 2017 | 12 | 0.150 |
Why?
|
Telepathology | 1 | 2018 | 77 | 0.150 |
Why?
|
Oxygen Consumption | 1 | 2024 | 1882 | 0.150 |
Why?
|
Lighting | 1 | 2020 | 211 | 0.150 |
Why?
|
Retinal Hemorrhage | 1 | 2018 | 98 | 0.140 |
Why?
|
Mice | 13 | 2024 | 82051 | 0.140 |
Why?
|
RNA, Messenger | 3 | 2024 | 12813 | 0.140 |
Why?
|
Pigment Epithelium of Eye | 1 | 2017 | 209 | 0.140 |
Why?
|
Mice, Inbred C57BL | 7 | 2020 | 22365 | 0.140 |
Why?
|
Fluorescent Antibody Technique, Indirect | 1 | 2017 | 426 | 0.140 |
Why?
|
CADASIL | 1 | 2017 | 83 | 0.140 |
Why?
|
Amyloid | 2 | 2019 | 852 | 0.130 |
Why?
|
Eye Foreign Bodies | 1 | 2016 | 51 | 0.130 |
Why?
|
Prostheses and Implants | 1 | 2023 | 1279 | 0.130 |
Why?
|
United States | 6 | 2024 | 73120 | 0.130 |
Why?
|
Optic Disk | 1 | 2020 | 422 | 0.130 |
Why?
|
Eye Injuries | 2 | 2016 | 228 | 0.130 |
Why?
|
Cross-Sectional Studies | 11 | 2024 | 26348 | 0.130 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2020 | 757 | 0.130 |
Why?
|
Psychotic Disorders | 2 | 2022 | 3278 | 0.130 |
Why?
|
Pericytes | 2 | 2017 | 299 | 0.120 |
Why?
|
Cornea | 1 | 2023 | 1332 | 0.120 |
Why?
|
Complement Pathway, Alternative | 1 | 2015 | 113 | 0.120 |
Why?
|
Breast Neoplasms | 2 | 2013 | 21157 | 0.120 |
Why?
|
Cell Proliferation | 4 | 2024 | 10490 | 0.120 |
Why?
|
Angiopoietin-1 | 1 | 2015 | 123 | 0.120 |
Why?
|
Eye Injuries, Penetrating | 1 | 2016 | 122 | 0.120 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 2016 | 750 | 0.120 |
Why?
|
Cell Culture Techniques | 2 | 2024 | 1669 | 0.120 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 1 | 2016 | 369 | 0.120 |
Why?
|
Cell Membrane | 1 | 2004 | 3663 | 0.120 |
Why?
|
Fibrinolysin | 1 | 2014 | 130 | 0.110 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 2 | 2016 | 548 | 0.110 |
Why?
|
Shal Potassium Channels | 2 | 2004 | 20 | 0.110 |
Why?
|
Charybdotoxin | 2 | 2003 | 23 | 0.110 |
Why?
|
Kv Channel-Interacting Proteins | 2 | 2004 | 40 | 0.110 |
Why?
|
Estrogen Antagonists | 1 | 2014 | 150 | 0.110 |
Why?
|
Comparative Genomic Hybridization | 1 | 2015 | 474 | 0.110 |
Why?
|
Telemedicine | 2 | 2024 | 3104 | 0.110 |
Why?
|
Immunohistochemistry | 3 | 2017 | 11139 | 0.110 |
Why?
|
Photoreceptor Cells, Vertebrate | 1 | 2015 | 203 | 0.110 |
Why?
|
COS Cells | 3 | 2004 | 1136 | 0.110 |
Why?
|
Retinal Degeneration | 3 | 2015 | 415 | 0.110 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2023 | 2884 | 0.110 |
Why?
|
Glial Fibrillary Acidic Protein | 1 | 2015 | 560 | 0.110 |
Why?
|
Extracellular Matrix Proteins | 1 | 2017 | 835 | 0.110 |
Why?
|
Kaplan-Meier Estimate | 1 | 2023 | 6537 | 0.100 |
Why?
|
Dependovirus | 1 | 2018 | 720 | 0.100 |
Why?
|
Macrophages | 1 | 2008 | 5797 | 0.100 |
Why?
|
Epithelial Cells | 2 | 2023 | 3697 | 0.100 |
Why?
|
Choroideremia | 1 | 2012 | 27 | 0.100 |
Why?
|
Connective Tissue Growth Factor | 1 | 2012 | 91 | 0.100 |
Why?
|
Genetic Vectors | 2 | 2022 | 3417 | 0.100 |
Why?
|
Cell Death | 2 | 2015 | 1684 | 0.100 |
Why?
|
Eyelid Neoplasms | 1 | 2013 | 89 | 0.100 |
Why?
|
Physical Examination | 1 | 2018 | 1262 | 0.100 |
Why?
|
Solutions | 1 | 2013 | 411 | 0.100 |
Why?
|
Schizophrenia | 2 | 2022 | 6987 | 0.100 |
Why?
|
Lymphatic Vessels | 1 | 2016 | 358 | 0.100 |
Why?
|
Vision, Ocular | 2 | 2022 | 458 | 0.100 |
Why?
|
Energy Metabolism | 1 | 2023 | 2901 | 0.100 |
Why?
|
Up-Regulation | 1 | 2020 | 4132 | 0.090 |
Why?
|
Glucose | 2 | 2020 | 4355 | 0.090 |
Why?
|
Caspases | 1 | 2014 | 884 | 0.090 |
Why?
|
History, 21st Century | 2 | 2020 | 1575 | 0.090 |
Why?
|
Codon, Nonsense | 1 | 2012 | 287 | 0.090 |
Why?
|
Case-Control Studies | 5 | 2024 | 22286 | 0.090 |
Why?
|
Hospitals, University | 1 | 2013 | 569 | 0.090 |
Why?
|
Fiducial Markers | 1 | 2012 | 134 | 0.090 |
Why?
|
Four-Dimensional Computed Tomography | 1 | 2012 | 142 | 0.090 |
Why?
|
Prospective Studies | 11 | 2024 | 54913 | 0.090 |
Why?
|
Learning | 1 | 2020 | 1762 | 0.090 |
Why?
|
Urination Disorders | 1 | 2011 | 238 | 0.090 |
Why?
|
Nystagmus, Optokinetic | 1 | 2010 | 31 | 0.090 |
Why?
|
Neurodegenerative Diseases | 1 | 2019 | 1095 | 0.090 |
Why?
|
Oxygen | 2 | 2019 | 4269 | 0.090 |
Why?
|
Cell Survival | 3 | 2016 | 5800 | 0.090 |
Why?
|
Technology Assessment, Biomedical | 2 | 2024 | 308 | 0.090 |
Why?
|
Aged, 80 and over | 11 | 2024 | 59679 | 0.090 |
Why?
|
Stomach Neoplasms | 1 | 2020 | 1484 | 0.090 |
Why?
|
Blotting, Western | 2 | 2014 | 5042 | 0.080 |
Why?
|
Survival Rate | 1 | 2023 | 12875 | 0.080 |
Why?
|
History, 20th Century | 2 | 2020 | 2772 | 0.080 |
Why?
|
Antibodies | 1 | 2017 | 2426 | 0.080 |
Why?
|
Colombia | 2 | 2021 | 285 | 0.080 |
Why?
|
Lysosomes | 1 | 2014 | 934 | 0.080 |
Why?
|
Cell Movement | 2 | 2017 | 5223 | 0.080 |
Why?
|
Interleukin-1beta | 1 | 2014 | 1021 | 0.080 |
Why?
|
Mutation | 5 | 2021 | 30235 | 0.070 |
Why?
|
Actins | 1 | 2015 | 2064 | 0.070 |
Why?
|
Genetic Association Studies | 1 | 2017 | 2742 | 0.070 |
Why?
|
Diagnosis, Differential | 2 | 2016 | 13025 | 0.070 |
Why?
|
tau Proteins | 1 | 2018 | 2130 | 0.070 |
Why?
|
Angiography | 2 | 2023 | 1597 | 0.070 |
Why?
|
Adipose Tissue, Brown | 1 | 2013 | 776 | 0.070 |
Why?
|
Capillaries | 2 | 2024 | 756 | 0.070 |
Why?
|
Motion Perception | 1 | 2010 | 379 | 0.070 |
Why?
|
Rabbits | 2 | 2024 | 4786 | 0.070 |
Why?
|
Adipocytes | 1 | 2013 | 1199 | 0.070 |
Why?
|
Microscopy, Electron | 2 | 2013 | 2565 | 0.070 |
Why?
|
Fibroblasts | 1 | 2016 | 4180 | 0.060 |
Why?
|
Radiotherapy Dosage | 1 | 2013 | 2925 | 0.060 |
Why?
|
Cell Hypoxia | 2 | 2019 | 661 | 0.060 |
Why?
|
Treatment Outcome | 6 | 2024 | 65408 | 0.060 |
Why?
|
Cyclosporine | 1 | 2008 | 781 | 0.060 |
Why?
|
Diarrhea | 1 | 2011 | 1320 | 0.060 |
Why?
|
Aging | 1 | 2024 | 8762 | 0.060 |
Why?
|
Fibrinolytic Agents | 1 | 2014 | 2082 | 0.060 |
Why?
|
Ischemia | 2 | 2023 | 1900 | 0.060 |
Why?
|
Adipose Tissue | 1 | 2016 | 3335 | 0.060 |
Why?
|
Head | 1 | 2010 | 927 | 0.060 |
Why?
|
Centrifugation, Density Gradient | 1 | 2003 | 298 | 0.060 |
Why?
|
Brain | 3 | 2020 | 27439 | 0.060 |
Why?
|
Apoptosis | 2 | 2017 | 9526 | 0.060 |
Why?
|
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone | 1 | 2023 | 20 | 0.050 |
Why?
|
Geographic Atrophy | 1 | 2024 | 92 | 0.050 |
Why?
|
Heparan Sulfate Proteoglycans | 1 | 2023 | 112 | 0.050 |
Why?
|
Phenotype | 2 | 2021 | 16712 | 0.050 |
Why?
|
Retinal Pigments | 1 | 2023 | 84 | 0.050 |
Why?
|
Adenocarcinoma | 1 | 2020 | 6400 | 0.050 |
Why?
|
Young Adult | 8 | 2024 | 60038 | 0.050 |
Why?
|
Gene Expression Regulation | 1 | 2020 | 11928 | 0.050 |
Why?
|
Glycerol | 1 | 2003 | 275 | 0.050 |
Why?
|
Bipolar Disorder | 1 | 2020 | 5125 | 0.050 |
Why?
|
Scotoma | 1 | 2023 | 128 | 0.050 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2012 | 2910 | 0.050 |
Why?
|
Molecular Targeted Therapy | 1 | 2013 | 2834 | 0.050 |
Why?
|
Patient Positioning | 1 | 2024 | 332 | 0.050 |
Why?
|
Antibodies, Bispecific | 1 | 2024 | 204 | 0.050 |
Why?
|
Peptide Fragments | 1 | 2014 | 5151 | 0.050 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 1 | 2003 | 1734 | 0.050 |
Why?
|
Models, Biological | 1 | 2017 | 9505 | 0.050 |
Why?
|
Practice Guidelines as Topic | 1 | 2018 | 7449 | 0.050 |
Why?
|
Regional Blood Flow | 1 | 2024 | 1503 | 0.040 |
Why?
|
Electrophysiology | 1 | 2003 | 1266 | 0.040 |
Why?
|
Membrane Potentials | 1 | 2004 | 1090 | 0.040 |
Why?
|
Emulsions | 1 | 2020 | 152 | 0.040 |
Why?
|
Molecular Structure | 1 | 2004 | 1889 | 0.040 |
Why?
|
Xenopus laevis | 1 | 2003 | 966 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 2 | 2021 | 18047 | 0.040 |
Why?
|
Sclera | 1 | 2020 | 190 | 0.040 |
Why?
|
Apolipoprotein E2 | 1 | 2019 | 135 | 0.040 |
Why?
|
Adrenal Cortex Hormones | 1 | 2008 | 1891 | 0.040 |
Why?
|
Pedigree | 2 | 2019 | 4545 | 0.040 |
Why?
|
Drug Therapy | 1 | 2021 | 504 | 0.040 |
Why?
|
Apolipoproteins E | 1 | 2023 | 1461 | 0.040 |
Why?
|
Disease Progression | 2 | 2024 | 13643 | 0.040 |
Why?
|
Databases, Factual | 2 | 2024 | 8081 | 0.030 |
Why?
|
Finite Element Analysis | 1 | 2019 | 441 | 0.030 |
Why?
|
Protein Structure, Tertiary | 1 | 2004 | 3790 | 0.030 |
Why?
|
Time Factors | 4 | 2021 | 40271 | 0.030 |
Why?
|
Reference Values | 1 | 2024 | 4941 | 0.030 |
Why?
|
Retinal Cone Photoreceptor Cells | 1 | 2018 | 184 | 0.030 |
Why?
|
Retinal Rod Photoreceptor Cells | 1 | 2018 | 204 | 0.030 |
Why?
|
Heterozygote | 1 | 2023 | 2792 | 0.030 |
Why?
|
Nerve Fibers | 1 | 2020 | 708 | 0.030 |
Why?
|
Carbolines | 1 | 2018 | 296 | 0.030 |
Why?
|
Early Diagnosis | 1 | 2021 | 1196 | 0.030 |
Why?
|
Kinetics | 1 | 2023 | 6347 | 0.030 |
Why?
|
Transduction, Genetic | 1 | 2018 | 903 | 0.030 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2019 | 9066 | 0.030 |
Why?
|
Homozygote | 1 | 2019 | 1779 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2003 | 10784 | 0.030 |
Why?
|
Vision Disorders | 1 | 2022 | 1092 | 0.030 |
Why?
|
Protein Binding | 2 | 2003 | 9376 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2023 | 1600 | 0.030 |
Why?
|
Intraocular Pressure | 1 | 2020 | 1304 | 0.030 |
Why?
|
Reoperation | 1 | 2024 | 4342 | 0.030 |
Why?
|
Diabetes Mellitus, Type 1 | 2 | 2020 | 3439 | 0.030 |
Why?
|
Skin Neoplasms | 1 | 2013 | 5891 | 0.030 |
Why?
|
Age of Onset | 1 | 2021 | 3342 | 0.030 |
Why?
|
Mice, Transgenic | 2 | 2017 | 9558 | 0.030 |
Why?
|
Reproducibility of Results | 2 | 2024 | 20232 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2016 | 560 | 0.030 |
Why?
|
Nanoparticles | 1 | 2024 | 1986 | 0.030 |
Why?
|
Gene Transfer Techniques | 1 | 2018 | 1209 | 0.030 |
Why?
|
Aniline Compounds | 1 | 2018 | 1094 | 0.030 |
Why?
|
Phosphorylation | 1 | 2023 | 8331 | 0.030 |
Why?
|
Cell Differentiation | 2 | 2024 | 11674 | 0.020 |
Why?
|
Aqueous Humor | 1 | 2012 | 153 | 0.020 |
Why?
|
Recurrence | 1 | 2024 | 8510 | 0.020 |
Why?
|
Macaca mulatta | 1 | 2018 | 2362 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2024 | 5532 | 0.020 |
Why?
|
Caspase 3 | 1 | 2013 | 732 | 0.020 |
Why?
|
Muscle, Smooth, Vascular | 1 | 2017 | 1494 | 0.020 |
Why?
|
Thiazoles | 1 | 2018 | 1541 | 0.020 |
Why?
|
Indocyanine Green | 1 | 2012 | 239 | 0.020 |
Why?
|
Rats, Transgenic | 1 | 2010 | 70 | 0.020 |
Why?
|
Nerve Tissue Proteins | 1 | 2023 | 4417 | 0.020 |
Why?
|
Urban Population | 1 | 2018 | 2047 | 0.020 |
Why?
|
Diabetes Mellitus, Type 2 | 3 | 2020 | 12242 | 0.020 |
Why?
|
Mice, Knockout | 2 | 2017 | 14483 | 0.020 |
Why?
|
Molecular Biology | 1 | 2013 | 573 | 0.020 |
Why?
|
Rhodopsin | 1 | 2010 | 199 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2013 | 20763 | 0.020 |
Why?
|
Prostatic Neoplasms | 1 | 2011 | 11206 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2024 | 14725 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2020 | 8559 | 0.020 |
Why?
|
Mass Screening | 1 | 2024 | 5455 | 0.020 |
Why?
|
Boston | 1 | 2021 | 9359 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2024 | 14766 | 0.020 |
Why?
|
Signal Transduction | 2 | 2023 | 23639 | 0.020 |
Why?
|
Rectum | 1 | 2011 | 902 | 0.020 |
Why?
|
Acute Disease | 1 | 2017 | 7245 | 0.020 |
Why?
|
Proteomics | 1 | 2020 | 3901 | 0.020 |
Why?
|
Sex Factors | 1 | 2020 | 10647 | 0.020 |
Why?
|
Imaging, Three-Dimensional | 1 | 2020 | 4077 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 4582 | 0.020 |
Why?
|
Species Specificity | 1 | 2010 | 2419 | 0.020 |
Why?
|
Prevalence | 1 | 2023 | 15879 | 0.020 |
Why?
|
Computer Simulation | 1 | 2019 | 6278 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 3813 | 0.020 |
Why?
|
Neuropsychological Tests | 1 | 2018 | 7133 | 0.020 |
Why?
|
Antigens, CD | 1 | 2015 | 4022 | 0.010 |
Why?
|
Adolescent | 3 | 2019 | 89163 | 0.010 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2011 | 1126 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2021 | 15459 | 0.010 |
Why?
|
Cognition Disorders | 1 | 2018 | 3984 | 0.010 |
Why?
|
Photic Stimulation | 1 | 2010 | 2005 | 0.010 |
Why?
|
Ultrasonography, Interventional | 1 | 2011 | 1520 | 0.010 |
Why?
|
Cognition | 1 | 2021 | 7062 | 0.010 |
Why?
|
Cell Line | 1 | 2016 | 15610 | 0.010 |
Why?
|
Prostate-Specific Antigen | 1 | 2011 | 2483 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2018 | 6657 | 0.010 |
Why?
|
Xenopus | 1 | 2003 | 710 | 0.010 |
Why?
|
Age Factors | 1 | 2018 | 18477 | 0.010 |
Why?
|
Inflammation | 1 | 2020 | 10863 | 0.010 |
Why?
|
Gene Expression | 1 | 2013 | 7605 | 0.010 |
Why?
|
Protein Subunits | 1 | 2003 | 943 | 0.010 |
Why?
|
Mitochondria | 1 | 2013 | 3672 | 0.010 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2003 | 2750 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2012 | 12450 | 0.010 |
Why?
|
Genotype | 1 | 2012 | 13045 | 0.010 |
Why?
|
Prognosis | 1 | 2015 | 30031 | 0.010 |
Why?
|
Rats | 1 | 2010 | 23839 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2003 | 13447 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2003 | 17637 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2018 | 36840 | 0.010 |
Why?
|
Child | 1 | 2015 | 80856 | 0.000 |
Why?
|